Cambrex Corporation (NYSE:CBM) and CTI BioPharma Corp. (NASDAQ:CTIC) compete against each other in the Biotechnology sector. We will compare them and contrast their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambrex Corporation	531.18M	2.44	93.21M	2.71	15.22
CTI BioPharma Corp.	26.29M	2.15	29.40M	-0.87	0.00

Table 1 highlights Cambrex Corporation and CTI BioPharma Corp.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides Cambrex Corporation and CTI BioPharma Corp.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Cambrex Corporation	17.55%	14.6%	9%
CTI BioPharma Corp.	-111.83%	-77.4%	-49.1%

Risk & Volatility

Cambrex Corporation’s current beta is 2.42 and it happens to be 142.00% more volatile than S&P 500. CTI BioPharma Corp.’s 1.59 beta is the reason why it is 59.00% more volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of Cambrex Corporation are 3.9 and 2.9 respectively. Its competitor CTI BioPharma Corp.’s Current Ratio is 3.6 and its Quick Ratio is 3.6. Cambrex Corporation can pay off short and long-term obligations better than CTI BioPharma Corp.

Analyst Ratings

In next table is delivered Cambrex Corporation and CTI BioPharma Corp.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cambrex Corporation	0	1	1	2.50
CTI BioPharma Corp.	0	0	0	0.00

Cambrex Corporation has a 11.72% upside potential and an average price target of $43.

Insider & Institutional Ownership

Cambrex Corporation and CTI BioPharma Corp. has shares held by institutional investors as follows: 0% and 61.1%. Insiders held 0.7% of Cambrex Corporation shares. Competitively, CTI BioPharma Corp. has 0.1% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cambrex Corporation	0.27%	-5.59%	-14.32%	-37.75%	-19.35%	9.14%
CTI BioPharma Corp.	21.23%	0%	-30.41%	-36.02%	-70.32%	62.21%

For the past year Cambrex Corporation has weaker performance than CTI BioPharma Corp.

Summary

Cambrex Corporation beats on 11 of the 12 factors CTI BioPharma Corp.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.